The estimated Net Worth of Robert E Abernathy is at least 25.4 百万$ dollars as of 11 August 2020. Mr. Abernathy owns over 4,000 units of Haemonetics stock worth over 872,878$ and over the last 22 years he sold HAE stock worth over 24,215,784$. In addition, he makes 270,188$ as Independent Director at Haemonetics.
Robert has made over 27 trades of the Haemonetics stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of HAE stock worth 323,720$ on 11 August 2020.
The largest trade he's ever made was selling 122,470 units of Haemonetics stock on 23 April 2012 worth over 9,368,955$. On average, Robert trades about 8,490 units every 70 days since 2003. As of 11 August 2020 he still owns at least 12,048 units of Haemonetics stock.
You can see the complete history of Mr. Abernathy stock trades at the bottom of the page.
Robert E. Abernathy serves as Independent Director of the Company. Mr. Abernathy served as Chairman and Chief Executive Officer of Halyard Health Inc., a medical technology company and spin-off from Kimberly-Clark, from October 2014 until his retirement in June 2017 (he continued as Chairman until September 2017). Mr. Abernathy joined Kimberly-Clark, a global personal care products company, in 1982 and held numerous roles of increasing responsibility, including President of Kimberly-Clark’s Global Health Care business, Group President, Developing & Emerging Markets, Managing Director, Kimberly-Clark Australia and President, North Atlantic Consumer Products. In addition to his current public company board service, Mr. Abernathy previously served as a director of Halyard Health, Inc. and RadioShack Corp.
As the Independent Director of Haemonetics, the total compensation of Robert Abernathy at Haemonetics is 270,188$. There are 9 executives at Haemonetics getting paid more, with Christopher Simon having the highest compensation of 9,398,200$.
Robert Abernathy is 65, he's been the Independent Director of Haemonetics since 2017. There are 4 older and 7 younger executives at Haemonetics. The oldest executive at Haemonetics Corp. is Richard Meelia, 71, who is the Independent Chairman of the Board.
Over the last 21 years, insiders at Haemonetics have traded over 82,114,016$ worth of Haemonetics stock and bought 334,931 units worth 14,646,550$ . The most active insiders traders include Paul Black、Robert E Abernathy、Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of 539,753$. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth 393,039$.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: